ArticleJAC-antimicrobial resistance2025
Molecular detection of carbapenemases in critical microorganisms since the onset of the COVID-19 pandemic in Peru.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbapenem-resistant Gram-negative pathogens: molecular epidemiology, diagnostic advances, and emerging therapeutic strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Identify and characterize carbapenemase genes in bacterial isolates of Enterobacterales, Methods: This retrospective, observational study analysed 2049 submitted due to suspected portability of carbapenemase genes, collected between January 2020 and August 2022. Samples were obtained from 61 hospitals in 18 of the 25 regions of Peru (72%) that participated in the National Surveillance AMR Program. Results: Among the isolates, 860 were Enterobacterales, 771 were Conclusion: This study highlights the significant detection of carbapenemase genes and their combinations in Peru during the COVID-19 pandemic. These findings underscore the urgent need for enhanced AMR surveillance, antimicrobial stewardship, and targeted infection control strategies to address this critical public health threat.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.